No correlation between COMT genotype and entacapone benefits in Parkinson's disease

Ji Seon Kim, Ji Young Kim, Jong Min Kim, Jae Woo Kim, Sun Ju Chung, Sung Reul Kim, Mi J. Kim, Hee Tae Kim, Kyoung Gyu Choi, Dong Ick Shin, Young Hee Sung, Kwang Soo Lee, Han Joon Kim, Jinwhan Cho, Mee Young Park, Hyun Young Park, Seong Min Choi, Kun Woo Park, Ho Won Lee, Tae Beom AhnOh Dae Kwon, Sang Jin Kim, Beom S. Jeon

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Catechol-O-methyltransferase (COMT) inhibitors are used to increase the bioavailability of therapeutic L-dopa. We examined the efficacy of entacapone in Parkinson's disease patients who had daily "off" duration of ≤2 hours, and carried different COMT polymorphisms. A total of 168 PD patients were recruited from 19 centers. Subjects were administered with 100-200 mg of entacapone in combination with each dose of L-dopa for 2 months. The clinical efficacy was evaluated based on the activities of daily living (ADL), score on the Unified Parkinson's Disease Rating Scale (UPDRS), Hoehn and Yahr (H&Y) stage, and Clinical Global Impression (CGI). COMT polymorphisms were genotyped. 3-O-methyldopa (3-OMD) levels were measured before and after the administration of entacapone. Entacapone administration produced significant improvements in the total daily "on" duration, ADL, UPDRS score, and H&Y stage. Nineteen patients (11.3%) had the low-activity COMT genotype, 68 patients (40.5%) had the intermediate-activity COMT genotype, and 81patients (48.2%) had the high-activity COMT genotype. The efficacy, and adverse effects of entacapone therapy did not differ between the three groups. There was a significant reduction in 3-OMD, but this did not differ among the three genotypes. Entacapone provided an increased "on" duration and improved motor function in all COMT genotypes.

Original languageEnglish
Pages (from-to)211-216
Number of pages6
JournalNeurology Asia
Volume16
Issue number3
Publication statusPublished - 2011 Oct 11

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'No correlation between COMT genotype and entacapone benefits in Parkinson's disease'. Together they form a unique fingerprint.

  • Cite this

    Kim, J. S., Kim, J. Y., Kim, J. M., Kim, J. W., Chung, S. J., Kim, S. R., Kim, M. J., Kim, H. T., Choi, K. G., Shin, D. I., Sung, Y. H., Lee, K. S., Kim, H. J., Cho, J., Park, M. Y., Park, H. Y., Choi, S. M., Park, K. W., Lee, H. W., ... Jeon, B. S. (2011). No correlation between COMT genotype and entacapone benefits in Parkinson's disease. Neurology Asia, 16(3), 211-216.